NCT05907759 2026-06-02Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman DiseaseNational Institutes of Health Clinical Center (CC)Phase 2 Recruiting28 enrolled